

Reference number(s)
2140-A

SPECIALTY GUIDELINE MANAGEMENT

RIBAVIRIN PRODUCTS (COPEGUS, MODERIBA, REBETOL, RIBASPHERE, RIBASPHERE RIBAPAK, RIBATAB, ribavirin capsules and tablets)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

Copegus

Copegus is indicated for the treatment of chronic hepatitis C (CHC) virus infection in combination with Pegasys in patients 5 years of age and older with compensated liver disease not previously treated with interferon alpha, and in adult CHC patients coinfecting with HIV.

Moderiba

Moderiba is indicated for the treatment of chronic hepatitis C (CHC) virus infection in combination with peginterferon alfa-2a in patients 5 years of age and older with compensated liver disease not previously treated with interferon alpha, and in adult CHC patients coinfecting with HIV.

Rebetol

Rebetol is indicated in combination with interferon alfa-2b (pegylated and nonpegylated) for the treatment of chronic hepatitis C (CHC) in patients 3 years of age and older with compensated liver disease.

Ribasphere/RibaPak

Ribasphere is indicated for the treatment of chronic hepatitis C (CHC) virus infection in combination with peginterferon alfa-2a in patients 5 years of age and older with compensated liver disease not previously treated with interferon alpha, and in adult CHC patients coinfecting with HIV.

All other indications are considered experimental/investigational and not medically necessary.

II. EXCLUSIONS

Exclusions to other antiviral drugs being used in combination with the requested drug apply. Refer to the SGM policy for each drug in the treatment regimen for applicable exclusions.

III. CRITERIA FOR APPROVAL

Hepatitis C virus (HCV) infection

Refer to the SGM of requested regimen for the specific criteria for approval and approval durations.

IV. REFERENCES

Reference number(s)
2140-A

1. Copegus [package insert]. South San Francisco, CA: Genentech USA, Inc.; August 2015.
2. Moderiba [package insert]. North Chicago, IL: AbbVie Inc.; December 2017.
3. Rebetol [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; January 2020.
4. Ribasphere/Ribapak [package insert]. Warrendale, PA: Kadmon Pharmaceuticals, LLC; September 2017.
5. AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. <https://www.hcvguidelines.org>. Last changes made on September 29, 2021. Accessed October 15, 2021.
6. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2020.
7. Viekira Pak [package insert]. North Chicago, IL: AbbVie Inc.; December 2019.
8. Zepatier [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; December 2019.
9. Epclusa [package insert]. Foster City, CA: Gilead Sciences, Inc.; June 2021.
10. Vosevi [package insert]. Foster City, CA: Gilead Sciences, Inc.; November 2019.